Anders Zetterberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anders Zetterberg has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
G Auer
Department of Oncology–Pathology, Karolinska Institutet, Cancer Center Karolinska SE-171 76 Stockholm, Sweden
4 shared publicationsG Forsslund
2 shared publicationsG Lundell
2 shared publicationsM Bäckdahl
2 shared publicationsP O Granberg
2 shared publicationsT Löwhagen
2 shared publications
Latest Publications
- Open Access
Large-scale correlations between eight key double strand break related data sets over the whole human genome
Eight different data sets, covering the whole human genome are compared with regard to their genomic distribution. A close correlation between cytological detected chiasma and MLH1 immunofluorescence sites with the recombination density distribution from the HapMap project was found. Sites with a high probability of chromatid breakage after exposure to low and high ionization density radiations are often located inside common and rare Fragile Sites (FSs) indicating that the common Radiation-Induced Breakpoint sites (RIBs) may be a new kind of more local fragility. Furthermore, Oncogenes and other cancer-related genes are commonly located in regions with an increased probability of rearrangements during genomic recombination, or in regions with high probability of copy number changes, possibly since these processes may be involved in oncogene activation and cancer induction. An increased CpG density is linked to regions of high gene density to secure high fidelity reproduction and survival. To minimize cancer induction these genes are often located in regions of decreased recombination density and/or higher than average CpG density. Interestingly, copy number changes occur predominantly at common RIBs and/or FSs at least for breast cancers with poor prognosis and they decrease weakly but significantly in regions with increasing recombination density and CpG density. It is compelling that all these datasets are influenced by the cells handling of double strand breaks and more generally DNA damage on its genome. In fact, the DNA repair genes are systematically avoiding regions with a high recombination density. This may be a consequence of natural selection, as they need to be intact to accurately handle repairable DNA lesions.
Open AccessLarge-scale correlations between eight key double strand break related data sets over the whole human genome
Eight different data sets, covering the whole human genome are compared with regard to their genomic distribution. A close correlation between cytological detected chiasma and MLH1 immunofluorescence sites with the recombination density distribution from the HapMap project was found. Sites with a high probability of chromatid breakage after exposure to low and high ionization density radiations are often located inside common and rare Fragile Sites (FSs) indicating that the common Radiation-Induced Breakpoint sites (RIBs) may be a new kind of more local fragility. Furthermore, Oncogenes and other cancer-related genes are commonly located in regions with an increased probability of rearrangements during genomic recombination, or in regions with high probability of copy number changes, possibly since these processes may be involved in oncogene activation and cancer induction. An increased CpG density is linked to regions of high gene density to secure high fidelity reproduction and survival. To minimize cancer induction these genes are often located in regions of decreased recombination density and/or higher than average CpG density. Interestingly, copy number changes occur predominantly at common RIBs and/or FSs at least for breast cancers with poor prognosis and they decrease weakly but significantly in regions with increasing recombination density and CpG density. It is compelling that all these datasets are influenced by the cells handling of double strand breaks and more generally DNA damage on its genome. In fact, the DNA repair genes are systematically avoiding regions with a high recombination density. This may be a consequence of natural selection, as they need to be intact to accurately handle repairable DNA lesions.
- Open Access
- 5 February 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 3
Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine
Extensive studies of the genetic aberrations related to human diseases conducted over the last two decades have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers. Over the time, a series of cutting-edge high-throughput genetic tests, such as microarrays and next-generation sequencing, have been developed and incorporated into routine clinical practice. Although it is a classical low-throughput cytogenetic test, fluorescence in situ hybridization (FISH) does not show signs of fading; on the contrary, it plays an increasingly important role in detecting specific biomarkers in solid and hematologic neoplasms and has therefore become an indispensable part of the rapidly developing field of personalized medicine. In this article, we have summarized the recent advances in FISH application for both de novo discovery and routine detection of chromosomal rearrangements, amplifications, and deletions that are associated with the pathogenesis of various hematopoietic and non-hematopoietic malignancies. In addition, we have reviewed the recent developments in FISH methodology as well.
- 5 February 2014
- Published by Springer Nature in Biomarker Research
- Vol. 2 (1) , 3
Open AccessFluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine
Extensive studies of the genetic aberrations related to human diseases conducted over the last two decades have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers. Over the time, a series of cutting-edge high-throughput genetic tests, such as microarrays and next-generation sequencing, have been developed and incorporated into routine clinical practice. Although it is a classical low-throughput cytogenetic test, fluorescence in situ hybridization (FISH) does not show signs of fading; on the contrary, it plays an increasingly important role in detecting specific biomarkers in solid and hematologic neoplasms and has therefore become an indispensable part of the rapidly developing field of personalized medicine. In this article, we have summarized the recent advances in FISH application for both de novo discovery and routine detection of chromosomal rearrangements, amplifications, and deletions that are associated with the pathogenesis of various hematopoietic and non-hematopoietic malignancies. In addition, we have reviewed the recent developments in FISH methodology as well.
- Open Access
- 29 July 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (3) , 513-519
Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer
The role of genomic instability and proliferative activity for development of distant metastases in breast cancer was analysed, and the relative contribution of these two risk factors was quantified. A detailed quantitative comparison was performed between Ki67 and cyclin A as proliferative markers. The frequency of Ki67 and cyclin A-positive cells was scored in the same microscopic areas in 428 breast tumours. The frequency of Ki67-positive cells was found to be highly correlated with the frequency of cyclin A-positive cells, and both proliferation markers were equally good to predict risk of distant metastases. The relative contribution of degree of aneuploidy and proliferative activity as risk markers for developing distant metastases was studied independently. Although increased proliferative activity in general was associated with an increased risk of developing distant metastases, ploidy level was found to be an independent and even stronger marker when considering the group of small (T1) node negative tumours. By combining proliferative activity and ploidy level, a large group of low risk breast tumours (39%) could be identified in which only a few percentage of the tumours (5%) developed distant metastases during the 9-year follow-up time period.
- 29 July 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 99 (3) , 513-519
Open AccessGenomic instability and proliferative activity as risk factors for distant metastases in breast cancer
The role of genomic instability and proliferative activity for development of distant metastases in breast cancer was analysed, and the relative contribution of these two risk factors was quantified. A detailed quantitative comparison was performed between Ki67 and cyclin A as proliferative markers. The frequency of Ki67 and cyclin A-positive cells was scored in the same microscopic areas in 428 breast tumours. The frequency of Ki67-positive cells was found to be highly correlated with the frequency of cyclin A-positive cells, and both proliferation markers were equally good to predict risk of distant metastases. The relative contribution of degree of aneuploidy and proliferative activity as risk markers for developing distant metastases was studied independently. Although increased proliferative activity in general was associated with an increased risk of developing distant metastases, ploidy level was found to be an independent and even stronger marker when considering the group of small (T1) node negative tumours. By combining proliferative activity and ploidy level, a large group of low risk breast tumours (39%) could be identified in which only a few percentage of the tumours (5%) developed distant metastases during the 9-year follow-up time period.
- 1 February 1996
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 8 (2) , 359-365
Relationship between oncogene amplification, aneuploidy and altered expression of p53 in breast cancer
Many studies have noted an association between amplification of single oncogenes and poor prognosis in breast cancer. We are investigating whether measurement of amplification in a larger number of proto-oncogenes increases the reliability of the prognostic information provided. As the first stage of this investigation, amplification (of c-erbB-2, cycD1, int-2, c-myc and MDM2), aneuploidy and altered expression of p53, which all indicate genetic instability, were studied in 117 primary breast adenocarcinomas. Amplification was correlated with aneuploidy (p=0.002) but not with altered expression of p53 even though the tumours with p53 overexpression were all aneuploid. Our results suggest that measurement of amplification is a potentially valuable prognostic factor.
- 1 February 1996
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 8 (2) , 359-365
Relationship between oncogene amplification, aneuploidy and altered expression of p53 in breast cancer
Many studies have noted an association between amplification of single oncogenes and poor prognosis in breast cancer. We are investigating whether measurement of amplification in a larger number of proto-oncogenes increases the reliability of the prognostic information provided. As the first stage of this investigation, amplification (of c-erbB-2, cycD1, int-2, c-myc and MDM2), aneuploidy and altered expression of p53, which all indicate genetic instability, were studied in 117 primary breast adenocarcinomas. Amplification was correlated with aneuploidy (p=0.002) but not with altered expression of p53 even though the tumours with p53 overexpression were all aneuploid. Our results suggest that measurement of amplification is a potentially valuable prognostic factor.
- 1 January 1986
- Vol. 152, 1-7
Prognostic value of nuclear DNA content in follicular thyroid tumours.
The prognostic value of nuclear DNA content in follicular thyroid tumours was studied in 65 patients. Forty-six (20 with follicular carcinoma and 26 with follicular adenoma) were alive at least 10 years after diagnosis, and 19 had died of follicular thyroid carcinoma 2 months to 13 years after diagnosis. DNA was measured in morphologically identified single tumour cells either on material from fine-needle aspiration biopsy or on histologic sections from the primary tumours. Metastases or locally recurrent tumour were also examined in ten cases. The tumours from the surviving patients had cells with DNA content comparable to that in normal cells, whereas the tumours from the nonsurvivors showed higher DNA values. Primary tumours had essentially the same DNA content as metastases or local recurrence in eight of the ten studied cases. The data suggest that DNA measurement in follicular thyroid tumours offers a valuable addition to standard clinical and microscopic analysis.
- 1 January 1986
- Vol. 152, 1-7
Prognostic value of nuclear DNA content in follicular thyroid tumours.
The prognostic value of nuclear DNA content in follicular thyroid tumours was studied in 65 patients. Forty-six (20 with follicular carcinoma and 26 with follicular adenoma) were alive at least 10 years after diagnosis, and 19 had died of follicular thyroid carcinoma 2 months to 13 years after diagnosis. DNA was measured in morphologically identified single tumour cells either on material from fine-needle aspiration biopsy or on histologic sections from the primary tumours. Metastases or locally recurrent tumour were also examined in ten cases. The tumours from the surviving patients had cells with DNA content comparable to that in normal cells, whereas the tumours from the nonsurvivors showed higher DNA values. Primary tumours had essentially the same DNA content as metastases or local recurrence in eight of the ten studied cases. The data suggest that DNA measurement in follicular thyroid tumours offers a valuable addition to standard clinical and microscopic analysis.
- 1 December 1984
- Vol. 96 (6) , 957-71
Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy.
Reasons cited for the routine performance of total thyroidectomy in patients with papillary thyroid carcinoma include: fear of multicentric neoplastic foci causing local recurrence and death; risk of anaplastic transformation of unresected multifocal microscopic carcinoma; toxicity of high-dose radioactive iodine to ablate normal thyroid remnants; and lack of reliable criteria for grading malignancy and identifying patients at high risk. However, autopsy studies have detected microscopic foci of papillary thyroid cancer as incidental findings in up to 24% of patients dead of other diseases. The prevalence of anaplastic transformation of papillary thyroid carcinoma as determined from reports in the literature is less than 1%. A retrospective investigation of 90 patients with papillary thyroid carcinoma derived from the Swedish National Cancer Registry showed no complications from radioiodine ablation of postoperative thyroid remnants in 45 patients. Retrospective analysis of the DNA content of tumors at the time of the initial operation showed a significant difference between a group of 10 patients who died of recurrent and metastatic papillary thyroid carcinoma and a group of 16 patients alive at least 10 years after operation despite distant metastases or recurrent cancer in the thyroid bed and/or cervical lymph nodes. The risk of permanent hypoparathyroidism is higher in patients after total thyroidectomy without apparent improvement in survival rates when compared with less extensive resections. Therefore it is proposed that the criteria for total thyroidectomy in patients with papillary thyroid carcinoma be limited to: tumors that clinically involve both lobes of the thyroid gland, extracapsular spread of cancer requiring enbloc resection, and reoperations where scarring prevents accurate delineation of the extent of the tumor. By differentiating patients at high risk for death from papillary thyroid carcinoma from patients at low risk, the measurement of DNA content may decrease the need for routine total thyroidectomy.
- 1 December 1984
- Vol. 96 (6) , 957-71
Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy.
Reasons cited for the routine performance of total thyroidectomy in patients with papillary thyroid carcinoma include: fear of multicentric neoplastic foci causing local recurrence and death; risk of anaplastic transformation of unresected multifocal microscopic carcinoma; toxicity of high-dose radioactive iodine to ablate normal thyroid remnants; and lack of reliable criteria for grading malignancy and identifying patients at high risk. However, autopsy studies have detected microscopic foci of papillary thyroid cancer as incidental findings in up to 24% of patients dead of other diseases. The prevalence of anaplastic transformation of papillary thyroid carcinoma as determined from reports in the literature is less than 1%. A retrospective investigation of 90 patients with papillary thyroid carcinoma derived from the Swedish National Cancer Registry showed no complications from radioiodine ablation of postoperative thyroid remnants in 45 patients. Retrospective analysis of the DNA content of tumors at the time of the initial operation showed a significant difference between a group of 10 patients who died of recurrent and metastatic papillary thyroid carcinoma and a group of 16 patients alive at least 10 years after operation despite distant metastases or recurrent cancer in the thyroid bed and/or cervical lymph nodes. The risk of permanent hypoparathyroidism is higher in patients after total thyroidectomy without apparent improvement in survival rates when compared with less extensive resections. Therefore it is proposed that the criteria for total thyroidectomy in patients with papillary thyroid carcinoma be limited to: tumors that clinically involve both lobes of the thyroid gland, extracapsular spread of cancer requiring enbloc resection, and reoperations where scarring prevents accurate delineation of the extent of the tumor. By differentiating patients at high risk for death from papillary thyroid carcinoma from patients at low risk, the measurement of DNA content may decrease the need for routine total thyroidectomy.